Janssen Search
Search results
DIA Leadership
Article Type: Disease Interception Accelerator DIA Leadership The DIA leadership team, representing a diverse cross-section of deep scientific research and development talent at Janssen, is united by one vision: to lead a new paradigm in healthcare ...
HIV Treatment and Prevention
Innovations in HIV Treatment and Prevention HIV absorption. Janssen is exploring innovative applications of our HIV medicines to improve treatment and prevention outcomes in hard-to-reach areas by finding ways to reduce the frequency of dosing. We’re also ...
Janssen Immunology Supports World Autoimmune Arthritis Day Through Donate A Photo
Janssen Immunology Supports World Autoimmune Arthritis Day Through Donate A Photo The Janssen Pharmaceutical Companies of Johnson & Johnson recognize World Autoimmune Arthritis Day on May 20, 2018, to raise awareness and support the millions of ...
Neurological and Neuromuscular Disorders: Leveraging shared pathology across diseases to broaden therapeutic opportunities
Neurological and Neuromuscular Disorders: Leveraging shared pathology across diseases to broaden therapeutic opportunities As part of our strategy to broaden our focus beyond neuropsychiatry, we acquired Momenta Pharmaceuticals and gained full rights to ...
Partnerships
COVID-19 News Redirect Tile BeneVir’s Oncolytic Virus Technology Offers a Unique Opportunity to Strengthen Janssen’s Immunotherapy Research Collaborating with Karolinska Institutet for Advanced Real-World Data Analysis Joining Forces to Fight Chagas ...
Imagine a World Free of IBD: IBD Stress Test QuickFire Challenge
Imagine a World Free of IBD: IBD Stress Test QuickFire Challenge As a growing population faces Inflammatory Bowel Disease (IBD), a worldwide community from over 50 countries came together to raise awareness and unite people worldwide in their fight ...
Fighting Multi-Drug Resistant Tuberculosis
Fighting Multi-Drug Resistant Tuberculosis (MDR-TB) Creating Long-Term, Sustainable Solutions More than 480,000 new cases of multi-drug resistant tuberculosis (MDR-TB) were reported worldwide in 2013, and only 20 percent of MDR-TB patients were enrolled ...
Microbiome Discovery and Development Congress
The inaugural Microbiome Discovery and Development Congress to be held in Berlin, Germany. This congress will bring together key opinion leaders and senior industry experts in microbiome drug discovery to discuss the latest innovative discovery strategies ...
James F. List, M.D., Ph.D.
JAMES F. LIST, M.D., PH.D. GLOBAL THERAPEUTIC AREA HEAD CARDIOVASCULAR & METABOLISM James F. List, M.D., Ph.D., is the Global Therapeutic Area Head of Cardiovascular & Metabolism (CVM), leading a global team focused on creating new solutions for ...
James List, M.D., Ph.D.
JAMES LIST, M.D., Ph.D. GLOBAL THERAPEUTIC AREA HEAD CARDIOVASCULAR & METABOLISM James F. List, M.D., Ph.D. is the Global Therapeutic Area Head of Cardiovascular & Metabolism (CVM), leading a global team focused on creating new solutions for ...